SCHEMBL4909316

SCHEMBL4909316

CCCc1[c]cnn1-c1ccc(Cl)cc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.37
NPC1 O15118 4/20 0.36
TSHR P16473 2/20 0.36
ELANE P08246 1/20 0.36
NOTUM Q6P988 1/20 0.36
RAB9A P51151 3/20 0.35
ALDH1A1 P00352 2/20 0.35
KMT2A Q03164 2/20 0.35
KDM4E B2RXH2 2/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
MEN1 O00255 1/20 0.35
HPGD P15428 1/20 0.35
ALOX12 P18054 1/20 0.35
NFKB1 P19838 1/20 0.35
NFKB2 Q00653 1/20 0.35
RELA Q04206 1/20 0.35
HSD17B10 Q99714 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
POLB P06746 1/20 0.33
KCNH2 Q12809 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1086390 0.83 USP2 (0.38) MAPTNPC1TSHRRAB9AALDH1A1
SCHEMBL2347651 0.78 NPC1 (0.42) MAPTNPC1TSHRELANENOTUM
SCHEMBL13990274 0.68 MAPT (0.50) MAPTNPC1TSHRNOTUMRAB9A
SCHEMBL28417638 0.67 PTGS2 (0.35) MAPTNPC1NOTUMRAB9AALDH1A1
SCHEMBL885439 0.67 PTGS1 (0.43) MAPTNPC1TSHRRAB9AKDM4E
SCHEMBL13990850 0.67 MAPT (0.52) MAPTNPC1TSHRRAB9AALDH1A1
SCHEMBL2900588 0.66 POLB (0.38) MAPTNPC1TSHRNOTUMRAB9A
SCHEMBL13990640 0.65 MAPT (0.47) MAPTNPC1TSHRRAB9AALDH1A1
SCHEMBL16927586 0.65 MAPT (0.46) MAPTNPC1RAB9AALDH1A1KMT2A
SCHEMBL10431266 0.63 KMT2A (0.35) MAPTALDH1A1KMT2AKDM4ESMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8283351-B2 Inhibiting cyctic fibrosis transmembrane conductance regulator polypeptide ; therapy for diarrhea and polycystic kidney disease INSTITUTE FOR ONEWORLD HEALTH (US) 2012-10-09 US disclosed
US-20080269206-A1 CFTR INHIBITOR COMPOUNDS AND USES THEREOF INSTITUTE FOR ONEWORLD HEALTH 2008-10-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269206-A1 CFTR INHIBITOR COMPOUNDS AND USES THEREOF CFTR, PKD1, PKD2 MAPT 4853/4885NPC1 228/4885TSHR 1884/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.